SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 7, 2008

MEDIVATION, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-32836	13-3863260
(State of jurisdiction)	(Commission File No.)	(IRS Employer Identification No.)

201 Spear Street, 3^rd Floor

San Francisco, California 94105

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (415) 543-3470

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On July 7, 2008, Medivation, Inc. filed a press release reporting the top-line results of the Phase 2 clinical trial of its investigational drug Dimebon^™ in patients with mild-to-moderate Huntington’s disease. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. The primary endpoint in this trial was safety and tolerability. The secondary endpoint was efficacy, as measured by the Mini Mental State Examination, the Unified Huntington’s Disease Rating Scale (UHDRS) and the Alzheimer’s Disease Assessment Scale-cognitive subscale. Due to an inadvertent error, Medivation’s prior disclosures incorrectly stated that the UHDRS was the primary efficacy endpoint of this trial.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press release, dated July 7, 2008, entitled “Medivation Announces Positive Top-Line Results from Phase 2 Dimebon Study in Huntington’s Disease”

- 1 -

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MEDIVATION, INC.
Dated: July 7, 2008	By:	/s/ C. Patrick Machado
		C. Patrick Machado
		Senior Vice President, Chief Financial Officer

EXHIBIT INDEX

99.1 Press release, dated July 7, 2008, entitled “Medivation Announces Positive Top-Line Results from Phase 2 Dimebon Study in Huntington’s Disease”